A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy
| Autor: | Constantin T. Yiannoutsos, Mark A. Henderson, Robert Timmerman, David J. Hoopes, Mark Tann, Achilles J. Fakiris, Ronald C. McGarry, James W. Fletcher, Mark Williams, Pei Fen Lin |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Pilot Projects Standardized uptake value Radiosurgery Article Fluorodeoxyglucose F18 Carcinoma Non-Small-Cell Lung medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Lung cancer Aged Neoplasm Staging Aged 80 and over Fluorodeoxyglucose Radiation medicine.diagnostic_test business.industry Middle Aged medicine.disease Primary tumor Radiation therapy Oncology Positron emission tomography Positron-Emission Tomography Female Dose Fractionation Radiation Radiology Radiopharmaceuticals Nuclear medicine business Emission computed tomography Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 76:789-795 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2009.02.051 |
| Popis: | Purpose Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non–small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials 14 consecutive patients with medically inoperable Stage I NSCLC were enrolled. All patients received SBRT to 60–66 Gy in three fractions. Patients underwent serial planned FDG-PET/computed tomography fusion imaging before SBRT and at 2, 26, and 52 weeks after SBRT. Results With median follow-up of 30.2 months, no patients experienced local failure. One patient developed regional failure, 1 developed distant failure, and 1 developed a second primary. The median tumor maximum standardized uptake value (SUV max ) before SBRT was 8.70. The median SUV max values at 2, 26, and 52 weeks after SBRT were 6.04, 2.80, and 3.58, respectively. Patients with low pre-SBRT SUV were more likely to experience initial 2-week rises in SUV, whereas patients with high pre-SBRT SUV commonly had SUV declines 2 weeks after treatment ( p = 0.036). Six of 13 patients had primary tumor SUV max >3.5 at 12 months after SBRT but remained without evidence of local disease failure on further follow-up. Conclusions A substantial proportion of patients may have moderately elevated FDG-PET SUV max at 12 months without evidence of local failure on further follow-up. Thus, slightly elevated PET SUV max should not be considered a surrogate for local treatment failure. Our data do not support routine serial FDG-PET/computed tomography for follow-up of patients receiving SBRT for Stage I NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|